通过构建重组复合表位免疫原,研究其免疫学活性,为研制HCV治疗性疫苗奠定基础。
In order to pave the way for developing HCV therapeutic vaccines, we construct the recombinant polyepitope antigen and study the immunity of it in vitro and in vivo.
为了解乙型脑炎(乙脑)减毒活疫苗弱毒株SA14 14 2神经毒力的减弱程度,本文对弱毒株及其原株SA14强毒株进行了猴体和小白鼠的致病性和病理学变化的比较试验。
In order to study the attenuation of neurovirulence of SA14 14 2 attenuated vaccine virus, monkeys and mice were tested with the strain and its parent SA14 virulent strain.
结论已成功构建了人hsp70与MAGE - 4抗原表位基因的原核表达载体,为疫苗研究提供了依据。
Conclusion the prokaryotic expression vector for HSP70 and MAGE-4 epitope genes was successfully constructed, which provided a basis for the development of vaccine.
If we did the experiment where on this booster we included not only the initial antigen but some unrelated antigen, the response to the unrelated antigen called B here, looks like a primary response.
如果实验中我们使用的后续疫苗,不仅包括原抗原,还包括一些无关抗原,这里将对无关抗原的应答称为B,该应答就如同初次免疫一样
应用推荐